NCT05633264Completed
A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan
Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan
Source: ClinicalTrials.gov · Last updated 3 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 369 (actual)
- First submitted
- 22 Nov 2022
- Start date
- 5 Dec 2022
- Primary completion date
- 28 May 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT05633264
What you commit to
- Study type: Observational
- Participants enrolled: 369
- From 5 Dec 2022 to the primary completion date, 28 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.
Who the study is looking for
- Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| EP Pharmaline Coordinator of this site? Confirm its status | Tosima-ku | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.